IPG Investment Advisors LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

IPG Investment Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 17.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,936 shares of the medical research company’s stock after acquiring an additional 281 shares during the period. IPG Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,028,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. United Services Automobile Association raised its position in shares of Thermo Fisher Scientific by 10.1% during the 4th quarter. United Services Automobile Association now owns 11,531 shares of the medical research company’s stock worth $6,121,000 after acquiring an additional 1,061 shares in the last quarter. JARISLOWSKY FRASER Ltd acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $1,102,000. S&CO Inc. increased its position in Thermo Fisher Scientific by 1.2% during the fourth quarter. S&CO Inc. now owns 38,978 shares of the medical research company’s stock worth $20,689,000 after buying an additional 453 shares during the period. Peak Asset Management LLC increased its position in Thermo Fisher Scientific by 3.7% during the fourth quarter. Peak Asset Management LLC now owns 3,194 shares of the medical research company’s stock worth $1,695,000 after buying an additional 114 shares during the period. Finally, Mitchell Sinkler & Starr PA increased its position in Thermo Fisher Scientific by 16.4% during the fourth quarter. Mitchell Sinkler & Starr PA now owns 732 shares of the medical research company’s stock worth $389,000 after buying an additional 103 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on TMO shares. Evercore ISI lifted their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Barclays boosted their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Robert W. Baird cut their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Finally, Citigroup initiated coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $605.31.

Get Our Latest Report on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 0.2 %

TMO traded down $0.98 on Monday, reaching $584.05. The company’s stock had a trading volume of 883,200 shares, compared to its average volume of 1,501,020. The stock has a market cap of $222.94 billion, a price-to-earnings ratio of 37.46, a price-to-earnings-growth ratio of 2.73 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The business’s 50 day moving average is $576.44 and its 200 day moving average is $548.15.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,000 shares of company stock worth $18,486,980. 0.34% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.